Claims for Patent: RE39548

Summary for Patent: RE39548

Title:	Interleukin-5 specific recombinant antibodies
Abstract:	An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
Inventor(s):	Bodmer; Mark William (Cambridge, GB), Athwal; Diljeet Singh (London, GB), Emtage; John Spencer (Del Mar, CA)
Assignee:	Celltech R&D Limited (Slough, Berkshire, GB)
Application Number:	10/012,579
Patent Claims:	1. A recombinant antibody molecule that specifically binds human Interleukin-5 antigen comprising a composite heavy chain and a composite light chain, said composite heavy chain and light chain forming a variable domain comprising acceptor antibody framework residues, said variable domain comprising corresponding donor residues from murine monoclonal 39D10 heavy chain variable region consisting of the sequence of SEQ ID No:6 at residues 31-35, 50-65 and 95-102 and at framework residues 23, 24, 27-30, 37, 49, 73, 76, 77, and 78, and corresponding donor residues from murine monoclonal antibody 39D10 light chain variable region consisting of the sequence of SEQ ID No:8 at residues 24--34, 50-56 and 89-97 and at framework residues 22, 68, and 71 according to the Kabat numbering system. 2. An antibody molecule according to claim 1 wherein the acceptor antibody framework residues for the composite heavy chain are human group III heavy chain residues, and the acceptor antibody framework residues for the composite light chain are human group I light chain residues. 3. A recombinant antibody molecule that specifically binds human Interleukin-5 antigen, comprising .[.the.]. .Iadd.a .Iaddend.heavy chain variable region amino acid sequence comprising .Iadd.residues 20-135 of .Iaddend.SEQ ID No: 28, and .[.the.]. .Iadd.a .Iaddend.light chain variable region amino acid sequence comprising .Iadd.residues 21-128 of .Iaddend.SEQ ID No: 26. 4. A composition comprising the antibody molecule of any one of claims 1, 2, or 3 in combination with a pharmaceutically acceptable carrier, diluent or excipient. .Iadd.5. A recombinant antibody molecule that specifically binds human interleukin-5 antigen comprising a composite heavy chain and a composite light chain, said composite heavy chain and light chain forming a variable domain comprising acceptor antibody framework residues, said variable domain comprising corresponding donor residues from murine monoclonal antibody 39D10 heavy chain variable region consisting of the sequence of SEQ ID NO:6 at residues 31-35, 50-65 and 95-102 and at framework residues 24, 27-30, 37, 49, 73, 76 and 78, and corresponding donor residues from murine monoclonal antibody 39D10 light chain variable region consisting of the sequence of SEQ ID No:8 at residues 24-34, 50-56 and 89-97 and at framework residues 68 and 71 according to the Kabat number system..Iaddend. .Iadd.6. A recombinant antibody molecule that specifically binds human Interleukin-5 antigen, comprising a heavy chain variable region encoded by SEQ ID No: 27 and a light chain variable region encoded by SEQ ID No:25..Iaddend. .Iadd.7. A composition comprising the antibody molecule of any one of claims 5 or 6 in combination with a pharmaceutically acceptable carrier, diluent, or excipient..Iaddend.

Details for Patent RE39548

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	March 23, 2016	RE39548	2014-06-17

International Patent Family for US Patent RE39548

Country	Patent Number	Estimated Expiration
South Africa	954990
World Intellectual Property Organization (WIPO)	9535375
United States of America	6734286
United States of America	6316227
United States of America	5998586